Key facts
- Notable investors include Brandon Capital, Curie.Bio.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Phrenix Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Phrenix Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phrenix Therapeutics
Developer of transformative therapeutics intended for cognitive impairments in schizophrenia. The company offers structure-guided design and disease-relevant analytical pharmacology of GPCR-targeted therapeutics, enabling individuals, families, and communities affected by these conditions to experience improved well-being.
- Sector
- Healthcare
- HQ
- Australia
- Founded
- 2022
- Employees
- 7
- Website
- phrenixtx.com/
- Ownership
- Privately Held (backing)
Phrenix Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phrenix Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phrenix Therapeutics in its N-PORT filings yet. We sweep new filings monthly.